Author's response to reviews

**Title:** Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

**Authors:**

Karel Decaestecker (karel.decaestecker@uzgent.be)
Gert De Meerleer (gert.demeerleer@uzgent.be)
Filip Ameye (Filip.Ameye@AZMMSJ.BE)
Valérie Fonteyne (valerie.fonteyne@uzgent.be)
Bieke Lambert (bieke.lambert@uzgent.be)
Steven Joniau (steven.joniau@uzleuven.be)
Louke Delrue (louke.delrue@uzgent.be)
Ignace Billiet (ignace.billiet@azgroeninge.be)
Wim Duthoy (wim.duthoy@azstlucas.be)
Sarah Junius (s.junius@chmouscron.be)
Wouter Huysse (wouter.huysse@uzgent.be)
Nicolaas Lumen (nicolaas.lumen@uzgent.be)
Piet Ost (piet.ost@ugent.be)

**Version:** 2  
**Date:** 19 June 2014

**Author's response to reviews:**

Dear editor-in-chief,

We hereby send you our trial protocol entitled.

As requested I have emailed the requested documentation concerning ethical and funding approval to BMCSeriesEditorial@biomedcentral.com. This study is funded by the Vlaamse Liga Tegen Kanker, an association without lucrative pruposes (www.vlk.be). This project ranked 1st in 2013 (http://www.tegenkanker.be/goedgekeurde_projecten). This study is currently recruiting patients. None of the results have been previously published.

I have added the following information in the first paragraph of the M&M section: This study is approved by the Ethics committee of the Ghent University Hospital (EC2012/156) and is registered on clinicaltrials.gov (NCT01558427).

Sincerely,

Piet Ost, M.D., Ph.D.

Corresponding author
Department of Radiotherapy, Ghent University Hospital, De Pintelaan 185, B-9000, Gent, Belgium

Tel: 0032 9 332 24 11, Fax: 0032 9 332 30 40, E-mail: piet.ost@ugent.be